XENCOR INC (XNCR:NASDAQ)
$29.82 0.61 (2.0883%)
Analysed XENCOR INC (XNCR:NASDAQ) News Sources
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
19-10-2026
yahoo.com
Is Xencor (XNCR) A Bargain After Its XmAb819 Phase 1 Update?
19-10-2026
yahoo.com
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
25-10-2026
yahoo.com
Xencor stock surges on positive cancer drug trial data
26-10-2026
yahoo.com
Xencor shares jump as kidney cancer drug data support Phase 3 plans
26-10-2026
proactiveinvestors.com
Xencor Soars 31% on Kidney Cancer Trial Data Showing “Impressive Antitumor Activity”
26-10-2026
tikr.com
Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer
26-10-2026
marketbeat.com
Xencor Catapults On 'Unprecedented,' 'Profound' Cancer Data
26-10-2026
yahoo.com
Xencor (XNCR) Is Up 15.8% What's Changed After Kidney Cancer Trial Update
26-10-2026
yahoo.com
Xencor Sees Upside Potential After 'Exciting' Kidney Cancer Trial Data, RBC Capital Markets Says
27-10-2026
yahoo.com
What is the current price of XENCOR INC (XNCR:NASDAQ)?
The current price of XENCOR INC (XNCR:NASDAQ) is $29.82.
XENCOR INC (XNCR:NASDAQ) absolute price change since previous trading day?
The absolute price change of XENCOR INC (XNCR:NASDAQ) since the previous trading day is $0.61.
XENCOR INC (XNCR:NASDAQ) percentage price change since previous trading day?
The percentage price change of XENCOR INC (XNCR:NASDAQ) since the previous trading day is 2.0883%.
What is the most recent average sentiment score for XENCOR INC (XNCR:NASDAQ)?
The most recent average sentiment score for XENCOR INC (XNCR:NASDAQ) is 86 out of 100.
What is the most recent average sentiment for XENCOR INC (XNCR:NASDAQ)?
The most recent sentiment for XENCOR INC (XNCR:NASDAQ) is .
SEC-8K** Filing Available For XENCOR INC (XNCR:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.